The Myotonic Dystrophy Foundation UK began grantmaking activities in 2015. The Myotonic Dystrophy Foundation UK has formed an alliance with the Myotonic Dystrophy Foundation in the United States to support selected basic and translational research projects, as a component of its efforts to accelerate therapy development. Information on the Myotonic Dystrophy Foundation is available here

Myotonic Dystrophy Foundation UK grant recipients include:

Research Grant Awards

  • The University of Utah, Primary Investigator Nicholas Johnson, M.D.: Population-based Prevalence Study in Myotonic Dystrophy Type-1 and Type-2
  • The Jackson Laboratory, Primary Investigator Cathleen Lutz, Ph.D.: Building a Better Mouse
  • Massachusetts General Hospital, Primary Investigator Thurman Wheeler, M.D.: Extracellular RNA as Biomarkers of Myotonic Dystrophy
  • RUCDR Infinite Biologics, Rutgers University, Primary Investigator Michael Sheldon, Ph.D.: DM Cell Line Library
  • University of Florida, Primary Investigator Donovan Lott, D.PT.: Development of Magnetic Resonance Imaging as an Endpoint in Myotonic Dystrophy Type 1
  • Newcastle University, Primary Investigator Hanns Lochmuller, Ph.D., PHENO-DM1 - DM1 Deep Phenotyping to Improve Delivery of Personalized Medicine and Assist in the Planning, Design and Recruitment of Clinical Trials
  • University of Florida - Icagen, Inc. Collaboration, Primary Investigators Andrew Berglund, Ph.D., University of Florida and Paul R. August, Ph.D., Vice President, Department Head -Discovery Biology, Icagen, Inc.: Inhibiting Transcription of CUG/CCUG Expanded Repeats with Small Molecules
  • The Critical Path Institute, Primary Investigator Jane Larkindale, DPhil.: Biomarker Qualification Project
  • University of Florida, Primary Investigator S.H. Subramony, M.D.: Myotonic Dystrophy Clinical Research Network Multicenter Study of Natural History and Genetic Modifiers in Myotonic Dystrophy Type 1
  • University of Iowa, Primary Investigator Laurie Gutmann, M.D.: Myotonic Dystrophy Clinical Research Network Multicenter Study of Natural History and Genetic Modifiers in Myotonic Dystrophy Type 1
  • University of Valencia, Primary Investigator Ruben Artero, Ph.D.: Support for publication and open access fee for a peer-reviewed Myotonic Dystrophy therapy paper

Fellowship Awards

  • Raphael Benhamou, Ph.D., Scripps Research Institute, Florida, U.S.: Targeting the RNA that Causes DM2 for Degradation with Small Molecules
  • Talita Conte, Ph.D., University of Montreal, Canada: Novel strategy targeting muscle stem cells as a therapeutic approach for myotonic dystrophy type 2
  • Jana Jenquin, Ph.D., University of Florida, U.S.: Improving the activity of diamidines for potential therapeutic use for patients with myotonic dystrophy types 1 and 2
  • Sarah Overby, University of Valencia, Spain: Restoration of MBNL proteins through miRNA blocking as DM1 therapy
  • Carl Shotwell, University of Florida, U.S.: Engineering Synthetic RNA Binding Proteins to Probe the Mechanisms of Myotonic Dystrophy and Development of Potential New Therapeutics
  • Shruti Choudhary, Ph.D., Scripps Research Institute Florida, U.S.: Selective and non-toxic small molecules that cleave r(CUG) repeats in DM1—optimization and evaluation as a therapeutic approach

More Information

Additional award information will be posted to this page as it becomes available. Click here to view a list of past grant recipients. For questions please contact:

Home / Grantees

© Myotonic Dystrophy Foundation. All rights reserved.